Eli Lilly Reaches $1 Trillion Market Value Fueled by Weight-Loss Drugs

Milestone Market Valuation

• 🎯 Eli Lilly achieved a $1 trillion market value on Friday, becoming the first drugmaker to join an elite group historically dominated by tech giants.
• 🚀 This valuation underscores Lilly's significant rise as a powerhouse in the weight-loss drug market.

Growth Drivers: Mounjaro and Zepbound

• 📈 The company's stock has experienced a rally of over 35% this year, largely propelled by the explosive growth of its weight-loss medications.
• 💊 While Novo Nordisk initially led the market, Lilly's drugs, Mounjaro and Zepbound, have gained substantial popularity, helping to surpass its rival in prescriptions.
• 📈 Since the launch of Zepbound in late 2023, Lilly's stock has surged by more than 75%, outperforming the S&P 500's over 50% rise in the same period.

Market Outlook and Valuation

• 💰 Wall Street analysts estimate the global weight-loss drug market to be worth $150 billion by 2030.
• 🤝 Lilly and Novo Nordisk are projected to control the majority of global sales within this burgeoning market.
• 📊 Lilly's stock price reached over $1,600 per share, resulting in a valuation of approximately 50 times its anticipated earnings over the next 12 months.